Literature DB >> 2079601

Both apolipoproteins B-48 and B-100 are synthesized and secreted by the human intestine.

J M Hoeg1, D D Sviridov, G E Tennyson, S J Demosky, M S Meng, D Bojanovski, I G Safonova, V S Repin, M B Kuberger, V N Smirnov.   

Abstract

Apolipoprotein B (apoB), an apolipoprotein associated with very low density lipoproteins and the atherogenic low density lipoproteins (LDL), directs the metabolism of lipoprotein particles in plasma by interacting with the LDL receptor. Utilizing human intestinal biopsy organ cultures, we have studied the synthesis of intestinal apoB in man. Intestinal organ cultures from normal adults (n = 6) were incubated in the presence of protease inhibitors in media supplemented with [35S]methionine. Media from these cultures were evaluated by sequential NaDodSO4 polyacrylamide gel electrophoresis, radioautography, and Western blot analyses, and intestinal biopsies were studied using immunohistochemistry. The relative abundance of apoB-100 and apoB-48 mRNA was assessed using reverse transcriptase-polymerase chain reaction followed by primer extension. Although apoB-48 was the principal isoprotein that was newly synthesized by intestinal organ cultures, apoB-100 was also synthesized and secreted by human intestinal organ cultures with 16 +/- 3% of the intestinal apoB mRNA coding for apoB-100. These results establish that apoB-100 is produced by the human intestine. The synthesis of the atherogenic apoB-100 by the intestine has pathophysiologic implications for the development of diet-induced atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2079601

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  9 in total

1.  Robert Graves Memorial Lecture. Diabetes and atherosclerosis--a gut review.

Authors:  G H Tomkin
Journal:  Ir J Med Sci       Date:  2002 Apr-Jun       Impact factor: 1.568

2.  Elevated triglyceride-rich lipoproteins in diabetes. A study of apolipoprotein B-48.

Authors:  A Curtin; P Deegan; D Owens; P Collins; A Johnson; G H Tomkin
Journal:  Acta Diabetol       Date:  1996-09       Impact factor: 4.280

3.  Development and partial characterisation of an antiserum against apolipoprotein B of the short-finned eel, Anguilla australis.

Authors:  Erin L Damsteegt; Hiroko Mizuta; Yuichi Ozaki; Naoshi Hiramatsu; Takashi Todo; Akihiko Hara; Shigeho Ijiri; Shinji Adachi; P Mark Lokman
Journal:  J Comp Physiol B       Date:  2014-03-11       Impact factor: 2.200

4.  Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation.

Authors:  M F Linton; R Gish; S T Hubl; E Bütler; C Esquivel; W I Bry; J K Boyles; M R Wardell; S G Young
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

5.  Apolipoprotein E polymorphism influences postprandial retinyl palmitate but not triglyceride concentrations.

Authors:  E Boerwinkle; S Brown; A R Sharrett; G Heiss; W Patsch
Journal:  Am J Hum Genet       Date:  1994-02       Impact factor: 11.025

6.  Lipid and apolipoprotein B48 transport in mesenteric lymph and the effect of hyperphagia on the clearance of chylomicron-like emulsions in insulin-deficient rats.

Authors:  I J Martins; A J Sainsbury; J C Mamo; T G Redgrave
Journal:  Diabetologia       Date:  1994-03       Impact factor: 10.122

7.  Chylomicron-retinyl palmitate clearance in type I hyperlipidemic families.

Authors:  D L Sprecher; S L Knauer; D M Black; L A Kaplan; A A Akeson; M Dusing; D Lattier; E A Stein; M Rymaszewski; D A Wiginton
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

8.  Alterations in apolipoprotein B-48 in the postprandial state in NIDDM.

Authors:  A Curtin; P Deegan; D Owens; P Collins; A Johnson; G H Tomkin
Journal:  Diabetologia       Date:  1994-12       Impact factor: 10.122

9.  Metabolism of triglyceride-rich lipoproteins during alimentary lipemia.

Authors:  F Karpe; G Steiner; T Olivecrona; L A Carlson; A Hamsten
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.